


# PRESCRIPTION DRUGS OUTLOOK


Worldwide sales of prescription drugs are set for strong growth over the next half-decade and most of this growth will be driven by the prospects for a raft of new products coming on the market. However, strong competition from generics, the loss of sales following patent expiration and the constant uncertainty over drug approvals puts these forecasts at risk

## GLOBAL PRESCRIPTION DRUG SALES (\$BN)


- Prescriptions excluding generics and orphans
- Generics
- Orphan drugs targeted at rare diseases




**6.3%**  
estimated compound annual growth in global prescription drug sales between 2016 and 2022



**\$169bn**  
of new sales expected in 2022 will come from the current research and development pharmaceutical pipeline, equal to around half



**\$343bn**  
of new sales in 2022 will be exposed to clinical and market access risk




## GLOBAL PRESCRIPTION DRUG SALES AT RISK FROM PATENT EXPIRATION (\$BN)

Sales at risk represent product sales in the year prior to patent expiry but allocated to the year of expiry




## GLOBAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT SPEND (\$BN)



## GLOBAL PRESCRIPTION AND OVER-THE-COUNTER DRUG SALES (\$BN)\*

COMPARING SALES IN 2015 AND 2022 BY CATEGORY

- 2015 sales
- 2022 sales
- Compound annual growth rate



\*Industry sales are based on the top 500 pharmaceutical and biotechnology companies

EvaluatePharma 2016